Longeveron Inc. - Class A Common stock (LGVN)

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

LGVN stock results show that Longeveron missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.

Small-cap stocks are on the rise once again as the Federal Reserve ponders cutting interest rates, which has held back the sector.

The good news on Lomecel-B comes at an opportune time for Longeveron and LGVN stock -- it could attract a buyer.

Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.

Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's safety and efficacy in treating Alzheimer's, demonstrating slowed disease progression, improved daily living activities, and minimized brain volume loss.

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!

Longeveron shares are trading lower by 15.9% during Thursday's session. The company announced a $9.0 million registered direct offering of 2.2 million shares of its common stock.